Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old.

Treatment of very old patients with non-Hodgkin's lymphoma remains controversial. Indeed, patients over 80 years old are usually not included in trials. We show here that addition of rituximab to reduced-dose CHOP chemotherapy seems to be a good compromise between toxicity and efficacy, allowing clinicians to treat very elderly patients with a curative intent.